Yi Qin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2300520/publications.pdf

Version: 2024-02-01

55 papers	2,356 citations	201674 27 h-index	223800 46 g-index
55 all docs	55 docs citations	55 times ranked	3706 citing authors

#	Article	IF	Citations
1	Lipid raft involvement in signal transduction in cancer cell survival, cell death and metastasis. Cell Proliferation, 2022, 55, e13167.	5.3	36
2	The Relationship of Redox With Hallmarks of Cancer: The Importance of Homeostasis and Context. Frontiers in Oncology, 2022, 12, 862743.	2.8	28
3	Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors. BMC Surgery, 2022, 22, 160.	1.3	5
4	FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. Redox Biology, 2021, 38, 101807.	9.0	135
5	SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. Cancer Letters, 2021, 499, 265-278.	7.2	16
6	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacologica Sinica, 2021, 42, 1725-1741.	6.1	53
7	Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Frontiers in Endocrinology, 2021, 12, 679000.	3.5	29
8	Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 691557.	3.5	15
9	FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. Acta Biochimica Et Biophysica Sinica, 2021, 53, 997-1008.	2.0	5
10	MTAP Deficiencyâ€“Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. Cancer Research, 2021, 81, 4964-4980.	0.9	15
11	Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nabâ€paclitaxel in pancreatic cancer. Clinical and Translational Medicine, 2021, 11, e398.	4.0	1
12	ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. Cancer Cell International, 2021, 21, 514.	4.1	5
13	SETD8 induces stemness and epithelial–mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. Acta Biochimica Et Biophysica Sinica, 2021, 53, 1614-1624.	2.0	7
14	Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Gut, 2020, 69, 888-900.	12.1	99
15	Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Oncogene, 2020, 39, 6572-6588.	5.9	21
16	Ferroptosis: Final destination for cancer?. Cell Proliferation, 2020, 53, e12761.	5.3	73
17	Pin1 promotes pancreatic cancer progression and metastasis by activation of NFâ€ºBâ€LÂ€18 feedback loop. Cell Proliferation, 2020, 53, e12816.	5.3	32
18	Function and regulation of Fâ€˜box/WD repeatâ€˜containing protein 7 (Review). Oncology Letters, 2020, 20, 1526-1534.	1.8	7

#	Article	IF	Citations
19	Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. American Journal of Cancer Research, 2020, 10, 1182-1193.	1.4	16
20	Management of solid pseudopapillary neoplasms of pancreas: A single center experience of 243 consecutive patients. Pancreatology, 2019, 19, 681-685.	1.1	38
21	Laparoscopic pancreaticoduodenectomy: are the best times coming?. World Journal of Surgical Oncology, 2019, 17, 81.	1.9	23
22	UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Cancer Letters, 2019, 452, 226-236.	7.2	99
23	Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Cancer Cell International, 2019, 19, 49.	4.1	19
24	PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Cell Communication and Signaling, 2019, 17, 30.	6.5	72
25	Homeodomainâ€interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. Cell Proliferation, 2019, 52, e12603.	5.3	29
26	Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis. Cancer Cell International, 2019, 19, 309.	4.1	24
27	PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. Cancer Research, 2019, 79, 133-145.	0.9	46
28	FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. American Journal of Cancer Research, 2019, 9, 2650-2664.	1.4	10
29	TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1Î± axis and indicates prognosis in pancreatic cancer. Cell Death and Disease, 2018, 9, 321.	6.3	45
30	<scp>dCK</scp> negatively regulates the <scp>NRF</scp>2/<scp>ARE</scp> axis and <scp>ROS</scp> production in pancreatic cancer. Cell Proliferation, 2018, 51, e12456.	5.3	22
31	Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?. Cellular and Molecular Life Sciences, 2018, 75, 1001-1012.	5.4	31
32	The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Theranostics, 2018, 8, 5072-5087.	10.0	139
33	Role of angiogenesis in pancreatic cancer biology and therapy. Biomedicine and Pharmacotherapy, 2018, 108, 1135-1140.	5.6	46
34	MiRâ€29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. International Journal of Cancer, 2018, 143, 2919-2931.	5.1	23
35	CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription. Theranostics, 2018, 8, 2549-2564.	10.0	44
36	Zinc finger E-box-binding homeobox 1 mediates aerobic glycolysisviasuppression of sirtuin 3 in pancreatic cancer. World Journal of Gastroenterology, 2018, 24, 4893-4905.	3.3	15

#	Article	IF	Citations
37	Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Research, 2017, 15, 201-212.	3.4	45
38	A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. International Journal of Oncology, 2017, 50, 1792-1800.	3.3	20
39	ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. Cancer Letters, 2017, 388, 303-311.	7.2	46
40	FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Oncology Reports, 2017, 38, 2069-2077.	2.6	23
41	Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Experimental and Molecular Medicine, 2017, 49, e406-e406.	7.7	108
42	Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. Journal of Cancer, 2017, 8, 3615-3622.	2.5	20
43	Energy sources identify metabolic phenotypes in pancreatic cancer. Acta Biochimica Et Biophysica Sinica, 2016, 48, 969-979.	2.0	24
44	GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma Metastasis. Cancer Cell, 2016, 30, 444-458.	16.8	174
45	Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 177-188.	7.4	18
46	Gas1 Inhibits Metastatic and Metabolic Phenotypes in Colorectal Carcinoma. Molecular Cancer Research, 2016, 14, 830-840.	3.4	51
47	Critical role of oncogenic KRAS in pancreatic cancer (Review). Molecular Medicine Reports, 2016, 13, 4943-4949.	2.4	27
48	New insights into perineural invasion of pancreatic cancer: More than pain. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 111-122.	7.4	39
49	FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 3950-3960.	7.0	72
50	ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer Letters, 2016, 374, 127-135.	7.2	104
51	Papillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: ÃÃprospective randomized trial. Surgery, 2015, 158, 1211-1218.	1.9	21
52	Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Letters, 2015, 360, 227-233.	7.2	37
53	ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Research, 2015, 25, 561-573.	12.0	112
54	Epithelialâ€“mesenchymal transition in pancreatic cancer: Is it a clinically significant factor?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 43-49.	7.4	29

#	Article	IF	Citations
55	LSD1 sustains pancreatic cancer growth via maintaining HIF1Î±-dependent glycolytic process. Cancer Letters, 2014, 347, 225-232.	7.2	63